Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

被引:161
作者
Hill, A
Hillmen, P
Richards, SJ
Elebute, D
Marsh, JC
Chan, J
Mojcik, CF
Rother, RP
机构
[1] Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds LS1 3EX, W Yorkshire, England
[2] St George Hosp, Sch Med, Dept Haematol, London, England
[3] Alex Pharmaceut Inc, Cheshire, CT USA
关键词
D O I
10.1182/blood-2005-02-0564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paroxysmal nocturnal hemoglobinuria (PNH) is a hematologic disorder characterized by clonal expansion of red blood cells (RBCs) lacking the ability to inhibit complement-mediated hemolysis. Eculizumab, a humanized monoclonal antibody that binds the C5 complement protein, blocks serum hemolytic activity. This study evaluated the long-term safety and efficacy of eculizumab in 11 patients with PNH during an open-label extension trial. After completion of an initial 12-week study, all patients chose to participate in the 52-week extension study. Eculizumab, administered at 900 mg every 12 to 14 days, was sufficient to completely and consistently block complement activity in all patients. A dramatic reduction in hemolysis was maintained throughout the study, with a decrease in lactate dehydrogenase (LDH) levels from 3110.7 IU/L before treatment to 622.4 IU/L (P =.002). The proportion of PNH type III RBCs increased from 36.7% at baseline to 58.4% (P=.005). The paroxysm rate of days with gross evidence of hemoglobinuria per patient each month decreased from 3.0 during screening to 0.2 (P <.001) during treatment. The median transfusion rate decreased from 1.8 U per patient each month before eculizumab treatment to 0.3 U per patient each month (P =.001) during treatment. Statistically significant improvements in quality-of-life measures were also maintained during the extension study. Eculizumab continued to be safe and well tolerated, and all patients completed the study. The close relationship between sustained terminal complement inhibition, hemolysis, and symptoms was demonstrated.
引用
收藏
页码:2559 / 2565
页数:7
相关论文
共 25 条
  • [1] PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) IS CAUSED BY SOMATIC MUTATIONS IN THE PIG-A GENE
    BESSLER, M
    MASON, PJ
    HILLMEN, P
    MIYATA, T
    YAMADA, N
    TAKEDA, J
    LUZZATTO, L
    KINOSHITA, T
    [J]. EMBO JOURNAL, 1994, 13 (01) : 110 - 117
  • [2] THE MECHANISM OF ACTION OF DECAY-ACCELERATING FACTOR (DAF) DAF INHIBITS THE ASSEMBLY OF C-3 CONVERTASES BY DISSOCIATING C2A AND BB
    FUJITA, T
    INOUE, T
    OGAWA, K
    IIDA, K
    TAMURA, N
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) : 1221 - 1228
  • [3] Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
    Hall, C
    Richards, S
    Hillmen, P
    [J]. BLOOD, 2003, 102 (10) : 3587 - 3591
  • [4] Hill A, 2004, BLOOD, V104, p772A
  • [5] Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    Hillmen, P
    Hall, C
    Marsh, JCW
    Elebute, M
    Bombara, MP
    Petro, BE
    Cullen, MJ
    Richards, SJ
    Rollins, SA
    Mojcik, CF
    Rother, RP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06) : 552 - 559
  • [6] ISOLATION AND CHARACTERIZATION OF A MEMBRANE-PROTEIN FROM NORMAL HUMAN-ERYTHROCYTES THAT INHIBITS REACTIVE LYSIS OF THE ERYTHROCYTES OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA
    HOLGUIN, MH
    FREDRICK, LR
    BERNSHAW, NJ
    WILCOX, LA
    PARKER, CJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (01) : 7 - 17
  • [7] A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins
    Jasinski, M
    Pantazopoulos, P
    Rother, RP
    van Rooijen, N
    Song, WC
    Molina, H
    Bessler, M
    [J]. BLOOD, 2004, 103 (07) : 2827 - 2834
  • [8] COMPLEMENT SPECIFIC ANTIBODIES - DESIGNING NOVEL ANTIINFLAMMATORIES
    MATIS, LA
    ROLLINS, SA
    [J]. NATURE MEDICINE, 1995, 1 (08) : 839 - 842
  • [9] Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
    Moyo, VM
    Mukhina, GL
    Garrett, ES
    Brodsky, RA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (01) : 133 - 138
  • [10] THE EFFECTS OF RECOMBINANT HUMAN HEMOGLOBIN ON ESOPHAGEAL MOTOR FUNCTION IN HUMANS
    MURRAY, JA
    LEDLOW, A
    LAUNSPACH, J
    EVANS, D
    LOVEDAY, M
    CONKLIN, JL
    [J]. GASTROENTEROLOGY, 1995, 109 (04) : 1241 - 1248